The persistence and antitumor efficacy of CAR-T cells are modulated by tonic signaling within the CDR

Int Immunopharmacol. 2024 Jan 5:126:111239. doi: 10.1016/j.intimp.2023.111239. Epub 2023 Nov 17.

Abstract

Chimeric antigen receptor (CAR) T cell therapy has demonstrated remarkable clinical efficacy, but challenges related to relapse and CAR-T cell exhaustion persist. One contributing factor to this exhaustion is CAR tonic signaling, where CAR-T cells self-activate without antigen stimulation, leading to reduced persistence and impaired antitumor activity. To address this issue, we conducted a preclinical study evaluating tonic signaling using nanobody-derived CAR-T cells. Our investigation revealed that specific characteristics of the complementary determining regions (CDRs), including low solubility, polarity, positive charge, energy, and area of ionic and positive CDR patches of amino acids, were associated with low antigen-independent tonic signaling. Significantly, we observed that stronger tonic signaling directly impacted CAR-T cell proliferation in vitro, consequently leading to CAR-T cell exhaustion and diminished persistence and effectiveness in vivo. Our findings provide compelling preclinical evidence and lay the foundation for the clinical assessment of CAR-T cells with distinct tonic signaling patterns. Understanding the role of CDRs in modulating tonic signaling holds promise for advancing the development of more efficient and durable CAR-T cell therapies, thereby enhancing the treatment of cancer and addressing the challenges of relapse in CAR-T cell therapy.

Keywords: Antitumor; CDR; Chimeric antigen receptor; Nanobody; Persistence; Tonic signaling.

MeSH terms

  • Humans
  • Immunotherapy, Adoptive
  • Receptors, Antigen, T-Cell* / metabolism
  • Receptors, Chimeric Antigen*
  • Recurrence
  • T-Lymphocytes

Substances

  • Receptors, Antigen, T-Cell
  • Receptors, Chimeric Antigen